Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

NCT03251417 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
11
Enrollment
OTHER
Sponsor class

Stopped Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal cancer, the potential benefit of present intervention is under re-evaluation.

Conditions

Interventions

Sponsor

Peking University

Collaborators